The DOI matches its Crossref record; 37 of the 40 references it cites were found in a registry or an index, and 3 are not checked yet.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
Open accessAbstract
BACKGROUND: The most appropriate targets for systolic blood pressure to reduce cardiovascular morbidity and mortality among persons without diabetes remain uncertain. METHODS: We randomly assigned 9361 persons with a systolic blood pressure of 130 mm Hg or higher and an increased cardiovascular risk, but without diabetes, to a systolic blood-pressure target of less than 120 mm Hg (intensive treatment) or a target of less than 140 mm Hg (standard treatment). The primary composite outcome was myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes. RESULTS: At 1 year, the mean systolic blood pressure was 121.4 mm Hg in the intensive-treatment group and 136.2 mm Hg in the standard-treatment group. The intervention was stopped early after a median follow-up of 3.26 years owing to a significantly lower rate of the primary composite outcome in the intensive-treatment group than in the standard-treatment group (1.65% per year vs. 2.19% per year; hazard ratio with intensive treatment, 0.75; 95% confidence interval [CI], 0.64 to 0.89; P<0.001). All-cause mortality was also significantly lower in the intensive-treatment group (hazard ratio, 0.73; 95% CI, 0.60 to 0.90; P=0.003). Rates of serious adverse events of hypotension, syncope, electrolyte abnormalities, and acute kidney injury or failure, but not of injurious falls, were higher in the intensive-treatment group than in the standard-treatment group. CONCLUSIONS: Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT01206062.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the Systolic Blood Pressure Intervention Trial, 261 patients at high cardiovascular risk who were already using antihypertensive drugs targeting a systolic BP of 120 mmHg had an approximately twofold risk of syncope vs. the control group targeting a systolic BP of 140 mmHg.”
From 2018 ESC Guidelines for the diagnosis and management of syncope (2018) · cites this paper as [261]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results have been interpreted to be generally consistent between the two trials, but ACCORD BP was viewed as underpowered due to the composite primary end point being less sensitive to blood pressure regulation (38,40).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury (AKI), were more common in the intensive treatment arm; risk of adverse outcomes needs to be weighed against the cardiovascular benefit of more intensive blood pressure lowering.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“The primary composite outcome of MI, coronary syndromes, stroke, heart failure, or death from cardiovascular causes was reduced by 25% in the intensive treatment group.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that treatment to a goal systolic blood pressure of <120 mmHg decreases cardiovascular event rates by 25% in high-risk individuals, although people with diabetes were excluded from this trial (38).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“The results of BPROAD and ESPRIT are supported by the Systolic Blood Pressure Intervention Trial (SPRINT), which demonstrated that treatment to a goal systolic blood pressure of <120 mmHg decreases cardiovascular event rates by 25% in high-risk individuals, although people with diabetes were excluded from this trial (44).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury (AKI), were more common in the intensive treatment arm”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [44]
In the citing paper
“in which there was a notable 25% relative/0.5% absolute reduced risk per year of cardiovascular morbidity and mortality with intensive (<120 mm Hg) as compared with standard (<140 mm Hg) systolic blood pressure control in patients with hypertension and high cardiovascular risk.71”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [71]
In the citing paper
“This graded approach is based on evidence from multiple meta-analyses and individual RCTs, which show a consistent and graded reduction in CVD risk in response to reductions in TC and LDL-C levels. 61-71”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [70]
In the citing paper
“These trials are consistent in showing that the higher the initial LDL-C level, the greater the absolute reduction in risk, while the relative risk reduction remains constant at any given baseline LDL-C level.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [70]
In the citing paper
“The primary composite outcome of myocardial infarction (MI), coronary syndromes, stroke, heart failure, or death from cardiovascular causes was reduced by 25% in the intensive treatment group.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that treatment to a target systolic blood pressure of < 120 mmHg decreases cardiovascular event rates by 25% in high-risk patients, although people with diabetes were excluded from this trial (33).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“Of note, the ACCORD BP and SPRINT trials targeted a similar systolic blood pressure < 120 mmHg, but in contrast to SPRINT, the primary composite cardiovascular end point was nonsigni fi cantly reduced in ACCORD BP.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“The achieved systolic blood pressures in the trial were 121 mmHg and 136 mmHg in the intensive versus standard treatment group, respectively.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury were more common in the intensive treatment arm; risk of adverse outcomes needs to be weighed against the cardiovascular bene fi t of more intensive blood pressure lowering.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“The results have been interpreted to be generally consistent between both trials, but ACCORD BP was viewed as underpowered due to the composite primary end point being less sensitive to blood pressure regulation (33).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Lim, S. S., Vos, T., Flaxman, A. D., Danaei, G., Shibuya, K., Adair-Rohani, H., AlMazroa, M. A., Amann, M., Anderson, H. R., Andrews, K. G., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61766-8 · Cited by 11,805
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782
Global burden of hypertension: analysis of worldwide data
Kearney, P. M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P. K., & He, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17741-1 · Cited by 8,698
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Self-citationHeart Disease and Stroke Statistics—2014 Update
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2013) · Circulation · doi:10.1161/01.cir.0000441139.02102.80 · Cited by 5,264
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
Flagged first, then by citations
Research works printed but not linked: 3
- 10.1016/s0140-6736(05)70151-3 · DOI
- Franklin SS, 1999, Pathol Biol (Paris), 47, 594
- Nwankwo T, 2013, NCHS Data Brief, 133, 1
Cited by
Sorted by citations
Items 101–200 of 1,036
Iadecola, C., Yaffe, K., Biller, J., Bratzke, L. C., Faraci, F. M., Gorelick, P. B., Gulati, M., Kamel, H., Knopman, D. S., Launer, L. J., et al. (2016) · Hypertension · doi:10.1161/hyp.0000000000000053 · Cited by 746
Tyson, C. C., & Coffman, T. M. (2017) · The Nephron journals/Nephron journals · doi:10.1159/000455130 · Cited by 715
Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease
Matsushita, K., Ballew, S. H., Wang, A. Y.-M., Kalyesubula, R., Schäeffner, E., & Agarwal, R. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00616-6 · Cited by 728
Diabetes and hypertension: a position statement by the American Diabetes Association
de Boer, I. H., Bangalore, S., Benetos, A., Davis, A. M., Michos, E. D., Muntner, P., Rossing, P., Zoungas, S., & Bakris, G. (2017) · Diabetes Care · doi:10.2337/dci17-0026 · Cited by 714
Blood pressure and the new ACC/AHA hypertension guidelines
Flack, J. M., & Adekola, B. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.05.003 · Cited by 714
Tsutsui, H., Isobe, M., Ito, H., Ito, H., Okumura, K., Ōno, M., Kitakaze, M., Kinugawa, K., Kihara, Y., Goto, Y., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0342 · Cited by 720
Metra, M., & Teerlink, J. R. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31071-1 · Cited by 701
Velleca, A., Shullo, M. A., Dhital, K. K., Azeka, E., Colvin, M. M., DePasquale, E. C., Farrero, M., García-Guereta, L., Jamero, G., Khush, K. K., et al. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.10.015 · Cited by 713
2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease
Isselbacher, E. M., Preventza, O. A., Black, J. H., Augoustides, J. G., Beck, A. W., Bolen, M. A., Braverman, A. C., Bray, B. E., Brown-Zimmerman, M. M., Chen, E. P., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.08.004 · Cited by 688
Stroke Epidemiology and Risk Factor Management
Guzik, A. K., & Bushnell, C. (2017) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000416 · Cited by 685
Effect of systolic and diastolic blood pressure on cardiovascular outcomes
Flint, A. C., Conell, C., Ren, X., Banki, N. M., Chan, S. L., Rao, V. A., Melles, R. B., & Bhatt, D. L. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1803180 · Cited by 684
de Vries, T. I., Cooney, M. T., Selmer, R. M., Hageman, S. H. J., Pennells, L. A. M., Wood, A., Kaptoge, S. K., Xu, Z., Westerink, J., Rabanal, K. S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab312 · Cited by 682
Halliday, A. W., & Bax, J. J. (2018) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2018.03.004 · Cited by 660
Tucker, K. L., Sheppard, J. P., Stevens, R., Bosworth, H. B., Bove, A., Bray, E. P., Earle, K., George, J., Godwin, M., Green, B. B., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002389 · Cited by 658
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
Bangalore, S., Rimoldi, S., & Messerli, F. H. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1602668 · Cited by 657
Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Lonn, E., Bosch, J., López-Jaramillo, P. A., Zhu, J., Liu, L., Pais, P. S., Díaz, R., Xavier, D., Sliwa, K. S., Dans, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600175 · Cited by 626
Hypertension in older adults: Assessment, management, and challenges
Oliveros, E., Patel, H. N., Kyung, S., Fugar, S. S., Goldberg, A. B., Madan, N., & Williams, K. A., Sr. (2019) · Clinical Cardiology · doi:10.1002/clc.23303 · Cited by 624
Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
DeFronzo, R. A., Reeves, W. B., & Awad, A. S. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00393-8 · Cited by 627
van Charante, E. P. M., Richard, E., Eurelings, L. S., van Dalen, J.-W., Ligthart, S. A., van Bussel, E. F., Hoevenaar-Blom, M. P., Vermeulen, M., & van Gool, W. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30950-3 · Cited by 611
Arterial hypertension in adults. Clinical guidelines 2020
Kobalava, Z. D., Конради, А. О., Nedogoda, S. V., Shlyakhto, E. V., Arutyunov, G. P., Баранова, Е. И., Барбараш, О. Л., Бойцов, С. А., Вавилова, Т. В., Вадимовна, В. С., et al. (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-3-3786 · Cited by 609
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
LeRoith, D., Biessels, G. J., Braithwaite, S. S., Casanueva, F. F., Draznin, B., Halter, J. B., Hirsch, I. B., McDonnell, M. E., Molitch, M. E., Murad, M. H., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00198 · Cited by 616
van der Flier, W. M., Skoog, I. G., Schneider, J. A., Pantoni, L., Mok, V., Chen, C., & Scheltens, P. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.3 · Cited by 606
Garovic, V. D., Dechend, R., Easterling, T., Karumanchi, S. A., McMurtry Baird, S., Magee, L. A., Rana, S., Vermunt, J. V., August, P., & on behalf of the American Heart Association Council on Hypertension; Council on the Kidney in Cardiovascular Disease, K. I. H. D. S. C. C. O. A. (2022) · Hypertension · doi:10.1161/hyp.0000000000000208 · Cited by 598
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.003 · Cited by 596
Martens, C. R., Denman, B. A., Mazzo, M. R., Armstrong, M. L., Reisdorph, N., McQueen, M. B., Chonchol, M., & Seals, D. R. (2018) · Nature Communications · doi:10.1038/s41467-018-03421-7 · Cited by 588
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab154 · Cited by 586
Rabi, D. M., McBrien, K. A., Sapir-Pichhadze, R., Nakhla, M., Ahmed, S. B., Dumanski, S. M., Butalia, S., Leung, A. A., Harris, K. C., Cloutier, L., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.02.086 · Cited by 583
Shlipak, M. G., Tummalapalli, S. L., Boulware, L. E., Grams, M. E., Ix, J. H., Jha, V., Kengne, A.-P., Madero, M., Mihaylova, B., Tangri, N., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.10.012 · Cited by 581
A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops
Victor, R. G., Lynch, K., Li, N., Blyler, C. A., Muhammad, E., Handler, J., Brettler, J. W., Rashid, M. A., Hsu, B., Foxx-Drew, D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1717250 · Cited by 565
Chung, M. K., Eckhardt, L. L., Chen, L. Y., Ahmed, H. M., Gopinathannair, R., Joglar, J. A., Noseworthy, P. A., Pack, Q. R., Sanders, P., & Trulock, K. M. (2020) · Circulation · doi:10.1161/cir.0000000000000748 · Cited by 565
Kittleson, M. M., Panjrath, G. S., Amancherla, K., Davis, L. L., Deswal, A., Dixon, D. L., Januzzi, J. L., & Yancy, C. W. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.03.393 · Cited by 554
Carey, R. M., & Whelton, P. K. (2018) · Annals of Internal Medicine · doi:10.7326/m17-3203 · Cited by 554
Heart Failure with Preserved Ejection Fraction
Redfield, M. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmcp1511175 · Cited by 520
Primary prevention of cardiovascular disease: A review of contemporary guidance and literature
Stewart, J., Manmathan, G. P. R., & Wilkinson, P. (2017) · JRSM Cardiovascular Disease · doi:10.1177/2048004016687211 · Cited by 516
Effects of Intensive BP Control in CKD
Cheung, A. K., Rahman, M., Reboussin, D. M., Craven, T. E., Greene, T., Kimmel, P. L., Cushman, W. C., Hawfield, A. T., Johnson, K., Lewis, C. E., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017020148 · Cited by 515
Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019
Précoma, D. B., de Oliveira, G. M. M., Simão, A. F. L., Dutra, Ó. P., Coelho-Filho, O. R., Izar, M. C. D. O., Póvoa, R., Giuliano, I. D. C. B., Filho, A. C. D. A., Machado, C. A., et al. (2019) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20190204 · Cited by 507
9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2018
(2017) · Diabetes Care · doi:10.2337/dc18-s009 · Cited by 505
Targeting vascular (endothelial) dysfunction
Daiber, A., Steven, S., Weber, A., Shuvaev, V. V., Muzykantov, V. R., Laher, I., Li, H., Lamas, S., & Münzel, T. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13517 · Cited by 501
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M. T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.05.037 · Cited by 502
Age and Sex Are Critical Factors in Ischemic Stroke Pathology
Roy-O’Reilly, M. A., & McCullough, L. D. (2018) · Endocrinology · doi:10.1210/en.2018-00465 · Cited by 498
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s010 · Cited by 495
Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda
Rohde, L. E. P., Montera, M. W., Bocchi, E. A., Clausell, N., de Albuquerque, D. C., Rassi, S., Colafranceschi, A. S., Freitas, A. F., Ferraz, A. S., Biolo, A., et al. (2018) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20180190 · Cited by 492
Macdougall, I. C., Bircher, A. J., Eckardt, K., Obrador, G. T., Pollock, C. A., Stenvinkel, P., Swinkels, D. W., Wanner, C., Weiß, G., Chertow, G. M., et al. (2016) · Kidney International · doi:10.1016/j.kint.2015.10.002 · Cited by 489
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s010 · Cited by 487
Mente, A., O'Donnell, M., Rangarajan, S., Dagenais, G., Lear, S., McQueen, M., Diaz, R., Avezum, A., Lopez-Jaramillo, P., Lanas, F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30467-6 · Cited by 483
Brunström, M., & Carlberg, B. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.6015 · Cited by 483
Ibáñez, B., James, S. K., Agewall, S., Antunes, M. J., Bucciarelli‐Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.11.010 · Cited by 479
2018 ESC Guidelines for the diagnosis and management of syncope
Brignole, M., Moya‐Mitjans, À., de Lange, F. J., Deharo, J., Elliot, P. M., Fanciulli, A., Fedorowski, A., Furlan, R., Kenny, R. A., Martiın, A., et al. (2018) · Kardiologia Polska · doi:10.5603/kp.2018.0161 · Cited by 475
Leung, A. A. C., Nerenberg, K. A., Daskalopoulou, S. S., McBrien, K., Zarnke, K. B., Dasgupta, K., Cloutier, L., Gelfer, M., Lamarre-Cliché, M., Milot, A., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.02.066 · Cited by 473
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s010 · Cited by 471
Vidal-Petiot, E., Ford, I., Greenlaw, N., Ferrari, R., Fox, K. M., Tardif, J.-C., Tendera, M., Tavazzi, L., Bhatt, D. L., & Steg, P. G. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31326-5 · Cited by 470
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s010 · Cited by 465
Neeland, I. J., Lim, S., Tchernof, A., Gastaldelli, A., Rangaswami, J., Ndumele, C. E., Powell-Wiley, T. M., & Després, J.-P. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00563-5 · Cited by 463
Treatment of hypertension: a review
Carey, R. M., Moran, A. E., & Whelton, P. K. (2022) · JAMA · doi:10.1001/jama.2022.19590 · Cited by 455
Final Report of a Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa1901281 · Cited by 454
Self-citationImmune mechanisms of hypertension
Drummond, G. R., Vinh, A., Guzik, T. J., & Sobey, C. G. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0160-5 · Cited by 447
Management of Hypertension in Chronic Kidney Disease
Pugh, D., Gallacher, P. J., & Dhaun, N. (2019) · Drugs · doi:10.1007/s40265-019-1064-1 · Cited by 445
Delgado, C., Baweja, M., Crews, D. C., Eneanya, N. D., Gadegbeku, C. A., Inker, L. A., Mendu, M. L., Miller, W. G., Moxey‐Mims, M., Roberts, G. V., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021070988 · Cited by 442
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Das, S. R., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s010 · Cited by 438
Al-Makki, A. A., DiPette, D., Whelton, P. K., Murad, M. H., Mustafa, R. A., Acharya, S., Beheiry, H. M., Champagne, B., Connell, K., Cooney, M. T., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.18192 · Cited by 435
Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions
Nasrallah, I. M., Pajewski, N. M., Auchus, A. P., Chelune, G. J., Cheung, A. K., Cleveland, M. L., Coker, L. H., Crowe, M. G., Cushman, W. C., Cutler, J. A., et al. (2019) · JAMA · doi:10.1001/jama.2019.10551 · Cited by 433
Bushnell, C., Kernan, W. N., Sharrief, A. Z., Chaturvedi, S., Cole, J. W., Cornwell, W. K., Cosby-Gaither, C., Doyle, S., Goldstein, L. B., Lennon, O. C., et al. (2024) · Stroke · doi:10.1161/str.0000000000000475 · Cited by 443
Privacy-Preserving Generative Deep Neural Networks Support Clinical Data Sharing
Beaulieu‐Jones, B. K., Wu, Z. S., Williams, C., Lee, R., Bhavnani, S. P., Byrd, J. B., & Greene, C. S. (2019) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.005122 · Cited by 430
Vascular Complications of Diabetes
Beckman, J. A., & Creager, M. A. (2016) · Circulation Research · doi:10.1161/circresaha.115.306884 · Cited by 432
Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., Bress, A. P., et al. (2025) · Hypertension · doi:10.1161/hyp.0000000000000249 · Cited by 424
Guideline for the diagnosis and management of hypertension in adults - 2016
Gabb, G. M., Mangoni, A. A., Anderson, C. S., Cowley, D., Dowden, J. S., Golledge, J., Hankey, G. J., Howes, F. S., Leckie, L., Perkovic, V., et al. (2016) · Medical Journal of Australia · doi:10.5694/mja16.00526 · Cited by 406
Aggarwal, R., Chiu, N., Wadhera, R. K., Moran, A. E., Raber, I., Shen, C., Yeh, R. W., & Kazi, D. S. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17570 · Cited by 406
Smith, E. E., Saposnik, G., Biessels, G. J., Doubal, F. N., Fornage, M., Gorelick, P. B., Greenberg, S. M., Higashida, R. T., Kasner, S. E., & Seshadri, S. (2017) · Stroke · doi:10.1161/str.0000000000000116 · Cited by 404
The Burden of Cardiovascular Diseases Among US States, 1990-2016
Roth, G. A., Johnson, C. O., Abate, K. H., Abd-Allah, F., Ahmed, M. B., Alam, K., Alam, S., Alvis‐Guzmán, N., Ansari, H., Ärnlöv, J., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.0385 · Cited by 402
Zoccali, C., Mallamaci, F., Adamczak, M., de Oliveira, R. B., Massy, Z. A., Sarafidis, P. A., Agarwal, R., Mark, P. B., Kotanko, P., Ferro, C. J., et al. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad083 · Cited by 399
The Burden of Hypertension and Associated Risk for Cardiovascular Mortality in China
Lewington, S., Lacey, B., Clarke, R., Yu, C., Kong, X. L., Yang, L., Chen, Y., Bian, Z., Chen, J., Meng, J., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.0190 · Cited by 396
Defining the relationship between hypertension, cognitive decline, and dementia: a review
Walker, K. A., Power, M. C., & Gottesman, R. F. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0724-3 · Cited by 394
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease
Yusuf, S., Lonn, E., Pais, P. S., Bosch, J., López-Jaramillo, P. A., Zhu, J., Xavier, D., Avezum, Á., Leiter, L. A., Piegas, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600177 · Cited by 380
Association of midlife to late-life blood pressure patterns with incident dementia
Walker, K. A., Sharrett, A. R., Wu, A., Schneider, A. L. C., Albert, M., Lutsey, P. L., Bandeen-Roche, K., Coresh, J., Gross, A. L., Windham, B. G., et al. (2019) · JAMA · doi:10.1001/jama.2019.10575 · Cited by 376
Brunström, M., & Carlberg, B. (2016) · BMJ · doi:10.1136/bmj.i717 · Cited by 375
Qaseem, A., Wilt, T. J., Rich, R., Humphrey, L. L., Frost, J., & Forciea, M. A. (2017) · Annals of Internal Medicine · doi:10.7326/m16-1785 · Cited by 365
Lifestyle Strategies for Risk Factor Reduction, Prevention, and Treatment of Cardiovascular Disease
Rippe, J. M. (2018) · American Journal of Lifestyle Medicine · doi:10.1177/1559827618812395 · Cited by 362
Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women
Cho, L., Davis, M. B., Elgendy, I. Y., Epps, K., Lindley, K. J., Mehta, P. K., Michos, E. D., Minissian, M., Pepine, C. J., Vaccarino, V., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.060 · Cited by 363
Diastolic Blood Pressure, Subclinical Myocardial Damage, and Cardiac Events
McEvoy, J. W., Chen, Y., Rawlings, A. M., Hoogeveen, R. C., Ballantyne, C. M., Blumenthal, R. S., Coresh, J., & Selvin, E. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.07.754 · Cited by 361
Suchard, M. A., Schuemie, M. J., Krumholz, H. M., You, S. C., Chen, R., Pratt, N., Reich, C. G., Duke, J., Madigan, D., Hripcsak, G., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32317-7 · Cited by 359
Rahimi, K., Bidel, Z., Nazarzadeh, M., Copland, E., Canoy, D., Wamil, M., Majert, J., McManus, R. J., Adler, A., Agodoa, L., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01921-8 · Cited by 356
Heart failure with preserved ejection fraction: from mechanisms to therapies
Lam, C. S. P., Voors, A. A., de Boer, R. A., Solomon, S. D., & van Veldhuisen, D. J. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy301 · Cited by 355
Cheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Ix, J. H., Knoll, G. A., Muntner, P., Pecoits‐Filho, R., Sarnak, M. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.10.026 · Cited by 353
Kullo, I. J., & Rooke, T. W. (2016) · New England Journal of Medicine · doi:10.1056/nejmcp1507631 · Cited by 351
Cardiorenal Syndrome Revisited
Zannad, F. M., & Rossignol, P. (2018) · Circulation · doi:10.1161/circulationaha.117.028814 · Cited by 351
Left ventricular hypertrophy and hypertension
Yildiz, M., Oktay, A. A., Stewart, M. H., Milani, R. V., Ventura, H. O., & Lavie, C. J. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.11.009 · Cited by 345
Li, Q., Yang, Y., Reis, C., Tao, T., Li, W., Li, X., & Zhang, J. H. (2018) · Cell Transplantation · doi:10.1177/0963689718795148 · Cited by 343
Potential U.S. Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline
Muntner, P., Carey, R. M., Gidding, S., Jones, D. W., Taler, S. J., Wright, J. T., & Whelton, P. K. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.10.073 · Cited by 339
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 339
Leung, A. A. C., Daskalopoulou, S. S., Dasgupta, K., McBrien, K., Butalia, S., Zarnke, K. B., Nerenberg, K. A., Harris, K. C., Nakhla, M. M., Cloutier, L., et al. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.03.005 · Cited by 334
Aortic Dilatation in Patients With Bicuspid Aortic Valve
Wang, J., Deng, W., Lv, Q., Li, Y., Liu, T., & Xie, M. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.615175 · Cited by 334
Coronary Artery Disease in Patients ≥80 Years of Age
Madhavan, M. V., Gersh, B. J., Alexander, K. P., Granger, C. B., & Stone, G. W. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.12.068 · Cited by 333
Levine, G. N., Lange, R. A., Bairey‐Merz, C. N., Davidson, R. J., Jamerson, K., Mehta, P. K., Michos, E. D., Norris, K., Ray, I. B., Saban, K. L., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.002218 · Cited by 330
Palaniappan, L. P., Allen, N. B., Almarzooq, Z., Anderson, C. A. M., Arora, P. K., Avery, C. L., Baker-Smith, C. M., Bansal, N., Currie, M. E., Earlie, R. S., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001412 · Cited by 343
Kario, K., Hoshide, S., Mizuno, H., Kabutoya, T., Nishizawa, M., Yoshida, T., Abe, H., Katsuya, T., Fujita, Y., Okazaki, O., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.049730 · Cited by 324
Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., Bress, A. P., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001356 · Cited by 335
Chronic Inflammation in Chronic Kidney Disease Progression: Role of Nrf2
Stenvinkel, P., Chertow, G. M., Devarajan, P., Levin, A., Andreoli, S. P., Bangalore, S., & Warady, B. A. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.04.023 · Cited by 327
Lees, J. S., Welsh, C. E., Celis-Morales, C. A., Mackay, D., Lewsey, J., Gray, S. R., Lyall, D. M., Cleland, J. G. F., Gill, J. M. R., Jhund, P. S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0627-8 · Cited by 319
Hypertension Across a Woman’s Life Cycle
WENGER, N. K., Arnold, A. M., Merz, C. N. B., Cooper‐DeHoff, R. M., Ferdinand, K. C., Fleg, J. L., Gulati, M., Isiadinso, I., Itchhaporia, D., Light-McGroary, K., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.033 · Cited by 318
Metadata
- Authors
- The SPRINT Research Group
- Affiliations
- University Hospitals Cleveland Medical Center (US)
- Corresponding author
- The SPRINT Research Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-26
- Volume
- 373
- Issue
- 22
- Pages
- 2103-2116
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4689591
- OpenAlex
- W3150595609
- Cited by
- 6,325
- References
- 38
- Citations by year
- 2026: 390 · 2025: 449 · 2024: 437 · 2023: 498 · 2022: 523 · 2021: 602 · 2020: 570 · 2019: 694 · 2018: 734 · 2017: 767 · 2016: 613 · 2015: 40
- FWCI
- 522.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000093, UL1TR000050, UL1TR001427, UL1TR000073, UL1TR001064, UL1TR001085, UL1TR000002, UL1TR000075, UL1TR000064, UL1TR000005, UL1TR000433, UL1TR000003, UL1TR000445, UL1TR000439, UL1TR000105)
- National Institute on Aging (P30AG021332)
- National Heart, Lung, and Blood Institute (HHSN268200900040C, A-HL-13-002-001, HHSN268200900049C, HHSN268200900048C, HHSN268200900047C, HHSN268200900046C)
- National Institute of General Medical Sciences (P30GM103337)
- National Center for Research Resources (UL1RR025755, UL1RR024134, UL1RR025752, UL1RR025771)
- National Center for Advancing Translational Sciences (9U54TR000017‐06)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Keywords
- intensive blood pressure control, systolic blood pressure target, antihypertensive therapy, cardiovascular risk, cardiovascular events, all-cause mortality, adverse events, hypotension, acute kidney injury, non-diabetic patients
- MeSH terms
- Age Factors, Aged, Antihypertensive Agents, Blood Pressure, Cardiovascular Diseases, Cause of Death, Female, Goals, Humans, Hypertension, Male, Middle Aged, Risk Factors, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
